PharmaIN is focused on formulating pharmaceutical compounds to optimize drug characteristics and target delivery to the intended tissue or receptor site. Two proprietary, platform technologies underpin our approach to the development of potent therapeutic products: Protected Graft Copolymer (PGC™) and PharmaIN Reversible Binding (PRB™).

Our technologies are paired with target molecules to achieve improved drug profile characteristics, including the following product improvements:
- Increased bio-distribution and useful circulating half-life
- Delivery of therapeutically effective drug doses to the intended tissue or receptor site
- Reduced toxicity
- More convenient patient treatment regimens (e.g. less frequent dosing)
- Improved solubilization and compound stability

Our innovative drug delivery can also provide potential significant commercial benefits:
- Differentiation from generic encroachment and potential new intellectual property
- Streamlined regulatory approvals
- Facilitation of multiple loading/synergistic therapies (e.g. more than one active agent or "payload" reversibly attached to carrier molecule).
- Application to potent small molecules, peptides, and protein molecules

Proof of concept has been demonstrated in multiple model systems, indicating compatibility with molecules and peptides for many diseases, including cancer and diabetes, among others.